Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 2, 2019

 

 

Proteostasis Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-37695		20-8436652
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
80 Guest Street, Suite 500 Boston, MA				02135
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code [phone]

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		PTI		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

---

Item 8.01.

Other Events.

On December 2, 2019, Proteostasis Therapeutics, Inc. (the “Company”) issued a press release announcing that it received a letter dated November 27, 2019 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the requirement of The Nasdaq Global Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5450 (a)(1), and that the matter is now closed. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit     No.		Exhibit Name
99.1		Press Release issued by the Company on December 2, 2019

---

EXHIBIT INDEX

 

Exhibit     No.		Exhibit Name
99.1		Press Release issued by the Company on December 2, 2019.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 2, 2019				PROTEOSTASIS THERAPEUTICS, INC.
				By:		/s/ Meenu Chhabra
						Meenu Chhabra
						President and Chief Executive Officer